cardiovascular research – Retraction Watch

Exclusive: Providence VA hires scientist previous employer found had harassed mentees

The University of Iowa found a cardiology researcher violated multiple of its policies, including harassing his former mentees when they tried to leave his lab to establish labs of their own, according to an investigation report obtained by Retraction Watch.

The researcher, Kaikobad Irani, left the school last month with a six-figure settlement, and has a new job lined up, Retraction Watch has learned.

Irani studies the molecular mechanisms of the function and dysfunction of blood vessels. He’s listed as an inventor on four patents, including an active one regarding a compound that could lower the risk of heart attacks and strokes.

One of Irani’s active grants names the Providence VA Medical Center as the awardee organization. A spokesperson for the VA Providence Healthcare System confirmed Irani “is in the process of onboarding and is expected to begin working around November.”

Exclusive: Cardiologist in Pakistan continued publishing after journal shown evidence he was running a paper mill

A cardiologist in Pakistan has been selling coauthorship of his research papers to scientists, particularly medical students, who were not involved in the work, Retraction Watch has learned. Several of his articles were published after the journal learned of his underhand activities.

Jahanzeb Malik, of the Rawalpindi Institute of Cardiology, publishes in a variety of journals, including Current Problems in Cardiology and Cardiology in Review, with a number of co-authors on each study.

However, not all of these authors contributed to the work. Malik, who is also a member of the Cardiovascular Analytics Group, an international network of researchers, runs a WhatsApp messaging group titled “Research Associates,” where he posts about articles he is working on and offers authorship “slots” in exchange for money, messages shown to Retraction Watch reveal. He has advertised on the “United States Medical Licensing Examination Pakistan” Group Facebook page, writing that he runs the group to “help students and other doctors in doing medical research and writing research papers.”

Going by the username “Darklord” on WhatsApp, Malik charges up to $300 for a first-author position. Less prominent positions on the manuscript can be bought for around $150. Malik has since changed his username to “Dr. Jahanzeb Malik” on the app.

University’s story changes: It requested 33 retractions, not ‘several’

The University of Wyoming has requested that journals retract 33 papers by a former associate dean and “highly cited researcher” at the institution.

The news came just a week after we broke the story that heart researcher Jun Ren had been demoted following an earlier investigation. At the time, a university spokesperson told us that “Based on the findings of this examination, the university is recommending retraction of several publications due to concerns regarding data irregularities inconsistent with published conclusions.”

A longtime whistleblower explains why he’s spent more than a decade trying to get a paper retracted

Since the report of the MIST Trial was published in Circulation in 2008, I have repeatedly written to the journal to express concern about the paper.

Most recently, on February 22, I wrote to the editor-in-chief of Circulation, which is owned by the American Heart Association (AHA), requesting that they retract the 2008 MIST Trial paper, the revised version of the paper, the correction and the data supplement. The response two days later was from the senior attorney of the AHA: “AHA respectfully declines any further involvement. We consider this matter closed and we will not pursue additional comment or review.”

Let me explain how I got involved, and why I have persisted. I was the principal cardiologist in the MIST Trial sponsored by NMT Medical. Another member of the steering committee (Simon Nightingale) and I refused to be authors of the paper because NMT had refused to allow any investigator to see all the data but even without access to the data it was clear that the paper made false claims. In November 2007, a few days after we refused to be authors, NMT started legal proceedings for libel and slander against me. They also instructed their lawyers to sue Nightingale, but did not start the legal proceedings against him.

Authors of meta-analysis on heart disease retract it when they realize a NEJM reference had been retracted

The authors of a meta-analysis on predicting cardiovascular disease have retracted the paper because it included a study that was retracted between the time they submitted their article and the date it was published.

If only there were a repository of retracted articles that authors and editors could check to see if the references in the studies they publish are still reliable.

Wait, we have one of those!

Harvard and the Brigham recommend 31 retractions for cardiac stem cell work

Retraction Watch readers may be familiar with the name Piero Anversa. Until several years ago, Anversa, a scientist at Harvard Medical School and the Brigham and Women’s Hospital, was a powerful figure in cardiac stem cell research.

“For ten years, he ran everything,” says Jeffery Molkentin, a researcher at Cincinnati Children’s whose lab was among the first to question the basis of Anversa’s results in a 2014 paper in Nature. Continue reading Harvard and the Brigham recommend 31 retractions for cardiac stem cell work

A distorted record on blood pressure drugs: Why one group is trying to clean up the literature

In 2015, a group of researchers based in Spain decided to write a review article on high blood pressure. But when they looked over eight articles co-authored by the same person, they noticed some undeniable similarities.

Over the last few years, Giuseppe Derosa, based at the University of Pavia in Italy, has racked up 10 retractions after journals determined he’d published the same material multiple times. But there’s much more to this story: The researchers in Spain (led by Luis Carlos Saiz of the Navarre Regional Health Service in Pamplona) kept digging into his publication record, and have since identified dozens of additional potential duplicates. Although the outside researchers alerted journals to the additional potentially problematic papers in 2015, most have not taken action; recently, two journals published by Taylor & Francis flagged 12 of Derosa’s articles, three of which they had been alerted about in 2015 by Saiz and colleagues.

Now, Saiz is telling his story — and why duplication of medical research matters:

Continue reading A distorted record on blood pressure drugs: Why one group is trying to clean up the literature

Authors retract heart disease paper for “nonscientific reason”

Researchers have retracted a 2018 paper about the genetic underpinnings of heart disease from the FASEB Journal — and it’s not entirely clear why.

The paywalled retraction notice simply cites a “nonscientific reason.” Cody Mooneyhan, the director of publications at the journal, declined to provide further details, and the authors have provided different accounts of what happened: The paper’s corresponding author, John Yu, told Retraction Watch that he requested the retraction because the first author, Chia‐Ti Tsai, refused to sign the journal’s copyright agreement. Tsai, a professor in the Department of Internal Medicine at National Taiwan University in Taipei, told us he was “not notified before the paper was submitted.” Continue reading Authors retract heart disease paper for “nonscientific reason”

Authors claim clinical trial data came from one center. It came from three.

A BMJ journal has retracted a 2017 paper that made a false claim about the clinical trial in question.

The Acupuncture in Medicine paper reported the results of a clinical trial about the impact of acupuncture and Chinese herbal medicine on stroke, gathered from one center. However, in November, the editors of the journal discovered that the authors had completed the trial at three centers, and had already published the data in Scientific Reports in 2016. The authors say the duplication and misrepresentation of the data stemmed from “confusion and misunderstanding.” Continue reading Authors claim clinical trial data came from one center. It came from three.

Caught Our Notice: Using this research tool? You’d better ask first

Title: Patient Education After CABG: Are We Teaching the Wrong Information?

What Caught Our Attention: We’ve written about the controversy surrounding a commonly used tool to measure whether patients are sticking to their drug regimen, known as the Morisky Medication Adherence Scale (MMAS-8). It can cost thousands of dollars — and using it without payment/permission earns researchers a call from a collector, who has used legal threats to compel multiple teams to withdraw their papers (a phenomenon we wrote about in Science). The creator of the tool argues it’s copyrighted, and demanding fees ensures researchers use it properly, which avoids putting patients at risk. We’ve found a notice (paywalled, tsk-tsk) that reveals another group of authors used the tool without permission and, according to the notice, “incorrectly.”

Continue reading Caught Our Notice: Using this research tool? You’d better ask first

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this: